fda glp-1 compounding crackdown news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Compounded GLP-1s: Why doctors worry

This is why GLP-1 and microbiome research often focuses on how microbial fermentation, gut barrier stability, and enteroendocrine signaling work together before hormone release occurs

For consumer goods companies, this represents both a challenge and an opportunity

Ideal candidates are those with a high BMI, comorbid conditions such as type 2 diabetes, and an elevated cardiovascular risk profile

however as the disease progresses, pathogens in the microbiome disable the immune response and immune exhaustion occurs (233, 234)

ISBN 9783319626413 Gum disease opens up the body to a host of infections April 6, 2016 Science News "Review and Analysis of the Literature on the Health Effects of Dental Amalgams" (PDF)